ORAL TREATMENT OF SEVERE PSORIASIS WITH A NEW AROMATIC RETINOID (RO 10-9359)

  • 1 January 1978
    • journal article
    • research article
    • Vol. 105  (10) , 813-818
Abstract
The aromatic retinoic acid derivative Ro 10-9359 [ethyl-all-trans-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate] was administered orally to 25 severe psoriatic patients (14 with generalized plaques, 7 erythrodermic, 4 pustular). The initial dose was 25 mg/20 kg body wt daily for 4 wk; afterwards the same posology was given every other day during several months (maximum 18 mo.). Excellent results were obtained in 16 patients (64%), particularly in severe erythrodermic and pustular psoriasis. Under follow-up therapy relapses sometimes occurred leading to temporary resumption of initial posology. The most important side effects are cheilitis, palmoplantar scaling with thinning of the skin, hyperhidrosis and diffuse hair loss. A slight increase of transaminases and of alkaline phosphatases was found in a few patients. The Ro 10-9359 compound is a very useful new therapy of severe psoriasis.

This publication has 0 references indexed in Scilit: